Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Theratechnologies Highlights Trogarzo Data At AIDS 2022; Co Says Data Shows Potential for Improved Treatment Regimens

New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents. Predictive pharmacokinetic modelling shows that new methods of
byBenzinga Newsdesk
July 28, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents.
  • Predictive pharmacokinetic modelling shows that new methods of administration could provide similar kinetics to intravenous infusion.
    • Additional data highlights synergistic activities between Trogarzo and dolutegravir, etravirine, tenofovir alafenamide and lenacapavir, a long-acting investigational antiretroviral therapy (ARV).
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Colgate-Palmolive Eyes Strong Levels of Brand Investment Following Q1 Performance, Raises Annual Revenue Growth Outlook

By Shivani Kumaresan
April 26, 8:44 AM
Colgate-Palmolive shares surge on Q1 FY24 sales growth, beating estimates with $5.065 billion revenue. Organic sales spike by 9.8%, driven by strong performance in Oral, Personal, and Home Care segments. CEO Noel Wallace emphasizes increased brand investment amid gross margin expansion. Explore Colgate's robust financials and upgraded FY24 outlook for deeper insights into its market strategy and growth trajectory.

CL